Inhibition of poly (ADP-ribose) glycohydrolase by gallotannin selectively up-regulates expression of proinflammatory genes

E Rapizzi, S Fossati, F Moroni, A Chiarugi - Molecular pharmacology, 2004 - ASPET
Molecular pharmacology, 2004ASPET
Poly (ADP-ribose)-polymerase-1 (PARP-1) and poly (ADP-ribose)(PAR) are emerging key
regulators of chromatin superstructure and transcriptional activation. Accordingly, both
genetic inactivation of PARP-1 and pharmacological inhibition of PAR formation impair the
expression of several genes, including those of the inflammatory response. In this study, we
asked whether poly (ADP-ribose) glycohydrolase (PARG), the sole depoly (ADP-ribosyl)
ating enzyme identified so far, also regulates gene expression. We report the novel finding …
Poly(ADP-ribose)-polymerase-1 (PARP-1) and poly(ADP-ribose) (PAR) are emerging key regulators of chromatin superstructure and transcriptional activation. Accordingly, both genetic inactivation of PARP-1 and pharmacological inhibition of PAR formation impair the expression of several genes, including those of the inflammatory response. In this study, we asked whether poly(ADP-ribose) glycohydrolase (PARG), the sole depoly(ADP-ribosyl)ating enzyme identified so far, also regulates gene expression. We report the novel finding that inhibition of PARG by gallotannin triggered nuclear accumulation of PAR and concomitant PAR-dependent expression of inducible NO synthase (iNOS) and cyclooxygenase-2 (COX-2), but not of interleukin-1β and tumor necrosis factor-α, in cultured RAW 264.7 macrophages. Remarkably, silencing of PARG by means of small interfering RNA selectively impaired gallotannin-induced expression of iNOS and COX-2. Consistent with a PAR-dependent transcriptional activation, increases of iNOS and COX-2 transcripts were not caused by activation of transcription factors such as nuclear factor-κB, activator protein-1, signal transducer and activator of transcription-1 or interferon regulatory factor-1, nor by mRNA stabilization. Overall, our data provide the first evidence that pharmacological inhibition of PARG leads to PAR-dependent alteration of gene expression profiles in macrophages.
ASPET